New stock news | China Resources Pharmaceutical Group submits its listing application to the Hong Kong Stock Exchange again.

According to the disclosure by the Hong Kong Stock Exchange on March 27, Nanjing Innovent Biologics, Inc. (Innovent Biologics) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Goldman Sachs and CICC as joint sponsors. The company previously submitted its application to the Hong Kong Stock Exchange on September 26, 2025. The prospectus shows that Innovent Biologics was established in 2009 and is a commercial-stage biotechnology company dedicated to advancing precision anti-cancer therapies based on synthetic lethality mechanisms globally, creating innovative therapies to meet the unmet medical needs of cancer patients. As of the latest practicable date, the company's pipeline includes (i) a core product developed independently called Senaparib, which has been commercialized in China as a first-line maintenance therapy for ovarian cancer, applicable to all populations regardless of mutation status. It is also being evaluated for its potential as a monotherapy for late-stage ovarian cancer patients with BRCA mutations who have received at least second-line standard systemic treatment, as a combination therapy for small cell lung cancer (SCLC) patients, and as a combination therapy for ovarian cancer patients who have received PARP inhibitors; and (ii) eleven other independently developed candidate drugs, including four clinical-stage candidates and seven pre-clinical stage candidates.